Overview

The problem SimuGen addresses

Toxicity is a leading contributor to the current stagnation in human drug innovation. Thanks to 'omic' technologies, many companies have created pre-clinical toxicogenomics programmes to begin addressing this concern.

Whilst this shift to molecular toxicology has helped slowly decipher possible mechanisms underlying particular toxicities, this approach has failed to create reliable, cost-effective or time-effective tests.

With high-throughput chemistry now making it easier to discover compounds with desired effects than compounds without the undesired effects, many programmes have been calling out for toxicogenomics to shift safety risk assessment into drug discovery, alongside predictive ADME.

What SimuGen can do for you

SimuGen differentiates itself as a pharmacogenomics company by focusing exclusively on drug discovery. Using best practice in human cell culture and SimuGen's breakthrough 'omic' models, drug discovery programme managers are able to seamlessly incorporate powerful risk assessment together with their current ADME workflows.

SimuGen doesn't rely on traditional hazard identification methods such as 'gene expression signatures', but explicitly models how genes are expressed with increasing toxicity over a wide spectrum of safety concerns. With the launch of SimuGen's flagship liver product, this means risk assessment of clinical endpoints such as fatty liver, zone 3 necrosis, jaundice or carcinogenesis within a framework of your drug safety priorities is now possible.

By submitting in vitro gene expression results from your lead compound programme to SimuGen's analysis servers you will not only be able to predict toxic outcomes, but also the relative doses at which these occur. Combining this with your input on the relative priority of various toxicities, you are able to thoroughly triage and risk-assess your programme for further analysis.